Plasmacytoma variant translocation 1 in cancer

Abstract

Abstract: Plasmacytoma variant translocation1（PVT1） is a very important long nocoding RNA, which located at chromosome 8q24.21 in human beings. Aberrant expression and polymorphism of PVT1 was closely associated with various kinds of cancers such as malignant lymphoma, breast cancer, colorectal cancer, pancreatic cancer, and affected survival and prognosis of cancer patients. This mainly attribute to its interactin with myc, miRNAs and other proteins, and also gene polymorphism. Further study of PVT1 is expected to provide a new target for the diagnosis and treatment of cancer.

Key words: Neoplasms, Plasmacytoma variant translocation 1

PENG Juan-Fei, ZHANG Shi-Neng. Plasmacytoma variant translocation 1 in cancer[J]. Journal of International Oncology, 2016, 43(2): 141-.

References

［1］ Fatica A, Bozzoni I. Long noncoding RNAs: new players in cell differentiation and development［J］. Nat Rev Genet, 2014, 15(1): 721. DOI:10.1038/nrg3606. ［2］ Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future［J］. Genetics, 2013, 193(3): 651669. DOI:10.1534/genetics.112.146704. ［3］ Qiu MT, Hu JW, Yin R, et al. Long noncoding RNA: an emerging paradigm of cancer research［J］. Tumor Biol, 2013, 34(2): 613620. DOI:1007/s1327701306586. ［4］ Guan Y, Kuo WL, Stilwell JL, et al. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer［J］. Clin Cancer Res, 2007, 13(19): 57455755. DOI:10.1158/10780432.CCR062882. ［5］ Yang YR, Zang SZ, Zhong CL, et al. Increased expression of the lncRNA PVT1 promotes tumorigenesis in nonsmall cell lung cancer［J］. Int J Clin Exp Pathol, 2014, 7(10): 69296935. ［6］ Ding J, Li D, Gong M, et al. Expression and clinical significance of the long noncoding RNA PVT1 in human gastric cancer［J］. OncoTargets Ther, 2014, 7: 16251630. DOI:10.2147/OTT.S68854. ［7］ Takahashi Y, Sawada G, Kurashige J, et al. Amplification of PVT1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers［J］. Br J Cancer, 2014, 110(1): 164171. DOI:10.1038/bjc.2013.698. ［8］ Cory S, Graham M, Webb E, et al. Variant (6;15) translocations in murine plasmacytomas involve a chromosome 15 locus at least 72 kb from the cmyc oncogene［J］. EMBO J, 1985, 4(3): 675681. ［9］ Shtivelman E, Bishop JM. The PVT gene frequently amplifies with MYC in tumor cells［J］. Mol Cell Biol, 1989, 9(3): 11481154. ［10］ Sen R, Ghosal S, Das S, et al. Competing endogenous RNA: the key to posttranscriptional regulation［J］. Sci World J, 2014, 2014: 896206. DOI:10.1155/2014/896206. ［11］ Tseng YY, Moriarity BS, Gong W, et al. PVT1 dependence in cancer with MYC copynumber increase［J］. Nature, 2014, 512(7512): 8286. DOI:10.1038/nature13311. ［12］ Barsotti AM, Beckerman R, Laptenko O, et al. p53dependent Induction of PVT1 and miR1204［J］. J Biol Chem， 2012, 287(4): 25092519. DOI:10.1074/jbc.M111.322875. ［13］ Paci P, Colombo T, Farina L. Computational analysis identifies a sponge interaction network between long noncoding RNAs and messenger RNAs in human breast cancer［J］. BMC Syst Biol, 2014, 8: 83. DOI:10.1186/17520509883. ［14］ EncisoMora V, Broderick P, Ma Y, et al. A genomewide association study of Hodgkin′s lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)［J］. Nat Genet, 2010, 42(12): 11261130. DOI:10.1038/ng.696. ［15］ Cerhan JR, Berndt SI, Vijai J, et al. Genomewide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma［J］. Nat Genet, 2014, 46(11): 12331238. DOI:10.1038/ng.3105. ［16］ Skibola CF, Berndt SI, Vijai J, et al. Genomewide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region［J］. Am J Hum Genet, 2014, 95(4): 462471. DOI:10.1016/j.ajhg.2014.09.004. ［17］ Meyer KB, Maia A, O′Reilly M, et al. A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression［J］. PLoS Genet, 2011, 7(7): e1002165. DOI:10.1371/journal.pgen.1002165. ［18］ Zhang Z, Zhu Z, Zhang B, et al. Frequent mutation of rs13281615 and its association with PVT1 expression and cell proliferation in breast cancer［J］. J Genet Genomics, 2014, 41(4): 187195. DOI:10.1016/j.jgg.2014.03.006. ［19］ Wang F, Yuan JH, Wang SB, et al. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem celllike property of hepatocellular carcinoma cells by stabilizing NOP2［J］. Hepatology, 2014, 60(4): 12781290. DOI:10.1002/hep.27239. ［20］ Liu E, Liu Z, Zhou Y. Carboplatindocetaxelinduced activity against ovarian cancer is dependent on upregulated lncRNA PVT1［J］. Int J Clin Exp Pathol, 2015, 8(4): 38033810. ［21］ Zhang XW, Bu P, Liu L, et al. Overexpression of long noncoding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance［J］. Biochem Biophys Res Commun, 2015, 462(3): 227232. DOI:10.1016/j.bbrc.2015.04.121. ［22］ Kong R, Zhang EB, Yin DD, et al. Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16［J］. Mol Cancer, 2015, 14: 82. DOI:10.1186/s1294301503558. ［23］ Cao WJ, Wu HL, He BS, et al. Analysis of long noncoding RNA expression profiles in gastric cancer［J］. World J Gastroenterol, 2013, 19(23): 36583664. DOI:10.3748/wjg.v19.i23.3658. ［24］ Ding C, Yang Z, Lv Z, et al. Long noncoding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients［J］. Oncol Lett, 2015, 9(2): 955963. DOI:10.3892/ol.2014.2730. ［25］ You L, Chang D, Du HZ, et al. Genomewide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells［J］. Biochem Biophys Res Commun, 2011, 407(1): 16. DOI:10.1016/j.bbrc.2011.02.027. ［26］ Iwakawa R, Takenaka M, Kohno T, et al. Genomewide identification of genes with amplification and/or fusion in small cell lung cancer［J］. Genes Chromosomes Cancer, 2013, 52(9): 802816. ［27］ Riquelme E, Suraokar MB, Rodriguez J, et al. Frequent coamplification and cooperation between CMYC and PVT1 oncogenes promote malignant pleural mesothelioma［J］. J Thorac Oncol, 2014, 9(7): 9981007. DOI:10.1097/JTO.0000000000000202. ［28］ Nagoshi H, Taki T, Hanamura I, et al. Frequent PVT1 rearrangement and novel chimeric genes PVT1NBEA and PVT1WWOX occur in multiple myeloma with 8q24 abnormality［J］. Cancer Res, 2012, 72(19): 49544962. DOI:10.1158/00085472.CAN120213. ［29］ Macchia G, Lonoce A, Venuto S, et al. A rare but recurrent t(8;13)(q24;q14) translocation in Bcell chronic lymphocytic leukaemia causing MYC upregulation and concomitant loss of PVT1, miR15/16 and DLEU7［J］. Br J Haematol, 2015, In press. DOI:10.1111/bjh.13482.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.